NCT01650285View on ClinicalTrials.gov

Cabazitaxel and Radiation For Patients With Prostate Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Prostate Cancer

Interventions

DRUG

Cabazitaxel

"Dose Level Day 1, 22, 43~1. 5.0 mg/m2~2. 10.0 mg/m2~3. 15.0 mg/m2~4. 20.0 mg/m2"

Trial Locations (1)

06902

Miriam Hospital, Providence

Sponsors

Lead Sponsor

Brown University

All Listed Sponsors

lead

Brown University

OTHER

NCT01650285 - Cabazitaxel and Radiation For Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter